9/18/13 - 9/17/16

NCI, HHSN261201200021I; Task Order # HHSN26100004 (PI: Grubbs)
Efficacy of metformin in the methylnitrosourea-induced model of ER+ mammary carcinogenesis when animals are placed on different diets: Standard diet, high fat diet, and high fructose diet.
The goal of this study is to determine if metformin might have mammary cancer preventive activity in obese or pre-diabetic animals.

9/18/13 - 9/17/16

NCI, HHSN261201200021I; Task Order # HHSN26100005 (PI: Grubbs) 
Evaluation of GLG-302, A STAT3 antagonist, in the prevention of mammary cancer.
The goal of this project is to evaluate the efficacy of a new STAT3 inhibitor, GLG-302, in the prevention of ER+ and ER- mammary cancers in rodents.

9/24/15 – 9/23/18

NCI, HHSN261201500036I; Task Order # HHSN26100002 (PI: Grubbs)
Evaluation of agents/protocols that inhibit two major pathways involved in human urinary bladder cancers (PI3K, EGFR) and protocols to reduce their toxicity.
The objective of this project is to evaluate two agents (MK2206 – and XL-147) for efficacy in the prevention of urinary bladder cancer in a chemically-induced rat model.

9/24/15 – 9/23/18

NCI, HHSN261201500036I; Task Order # HHSN26100003 (PI: Grubbs)
Evaluation of the cancer prevention efficacy of GLG-302.
The objective of this project is to evaluate a new formulation of GLG-302 in the prevention of ER+ and ER- mammary cancers in rodents.